降尿酸治疗与痛风患者全关节置换风险
基于台湾全民健康保险数据库和英国临床实践研究数据链,纳入台湾74560例和英国34505例新发痛风患者并按年龄性别匹配对照,发现痛风患者全关节置换风险显著升高(台湾调整HR 1.56,英国调整HR 1.14),且当前降尿酸治疗未降低该风险。
要点
- 痛风患者全关节置换风险显著高于无痛风者,台湾调整HR 1.56(95%CI 1.45,1.68),英国调整HR 1.14(95%CI 1.05,1.22)。
- 与降尿酸治疗累积限定日剂量<28者相比,各剂量组全关节置换调整OR均未达统计学显著。
- 基于两个国家人群的证据显示,当前降尿酸治疗未降低痛风患者全关节置换风险。
核心结论
- 基于两个国家人群的研究提供证据表明,痛风带来显著的全关节置换风险,而当前降尿酸治疗未降低该风险。
研究设计与样本
- 使用台湾全民健康保险数据库和英国临床实践研究数据链,识别台湾74560例和英国34505例新发痛风患者,并按年龄和性别与无痛风者匹配。
- 采用Cox比例风险模型和条件logistic回归分析痛风患者全关节置换风险及降尿酸治疗累积限定日剂量与全关节置换的关联。
主要发现
- 诊断痛风时全关节置换患病率:台湾痛风患者1.16% vs 无痛风者0.82%;英国痛风患者2.61% vs 无痛风者1.76%。
- 痛风诊断后全关节置换发生率:台湾痛风患者3.23 vs 无痛风者1.91例/1000人年;英国痛风患者6.87 vs 无痛风者4.61例/1000人年。
- 痛风患者全关节置换调整HR:台湾1.56(95%CI 1.45,1.68),英国1.14(95%CI 1.05,1.22)。
- 与降尿酸治疗累积限定日剂量<28者相比,台湾28-90、90-180、>180累积限定日剂量组全关节置换调整OR分别为0.89(95%CI 0.77,1.03)、1.03(95%CI 0.85,1.24)、1.12(95%CI 0.94,1.34)。
- 英国相应累积限定日剂量组全关节置换调整OR分别为1.09(95%CI 0.83,1.42)、0.93(95%CI 0.68,1.27)、1.08(95%CI 0.94,1.24)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine whether gout is an independent risk factor for total joint replacement (TJR) and whether urate-lowering treatment (ULT) reduces this risk. METHODS: Using the Taiwan National Health Insurance database and the UK Clinical Practice Research Datalink, 74 560 Taiwan patients and 34 505 UK patients with incident gout were identified and age and sex matched to people without gout. Cox proportional hazards models and condition logistic regression were used to examine the risk of TJR in gout patients and the association between cumulative defined daily dose (cDDD) of ULT and TJR. RESULTS: The prevalence rates of TJR in the patients at the time of diagnosis of gout and in people without gout were 1.16% vs 0.82% in Taiwan and 2.61% vs 1.76% in the UK. After a gout diagnosis, the incidence of TJR was higher in the patients with gout compared with those without (3.23 vs 1.91 cases/1000 person-years in Taiwan and 6.87 vs 4.61 cases/1000 person-years in the UK), with adjusted HRs of 1.56 (95% CI 1.45, 1.68) in Taiwan and 1.14 (1.05, 1.22) in the UK. Compared with patients with gout with <28 cDDD ULT, the adjusted ORs for TJR were 0.89 (95% CI 0.77, 1.03) for 28-90 cDDD, 1.03 (0.85, 1.24) for 90-180 cDDD and 1.12 (0.94, 1.34) for >180 cDDD ULT in Taiwan. In the UK, the respective ORs were 1.09 (0.83, 1.42), 0.93 (0.68, 1.27) and 1.08 (0.94, 1.24). CONCLUSION: This population-based study provides evidence from two nation populations that gout confers significant TJR risk, which was not reduced by current ULT.
引用
- Kuo CF, Chou IJ, See LC, et al. Urate-lowering treatment and risk of total joint replacement in patients with gout. Rheumatology (Oxford). 2018. PMID: 30060176. doi:10.1093/rheumatology/key212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。